Neurogene Inc. Finance Lease, Right-of-Use Asset, before Accumulated Amortization
Neurogene Inc. (NGNE) had Finance Lease, Right-of-Use Asset, before Accumulated Amortization of $22.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Leases › Assets and Liabilities, Lessee
us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization · last filed 2026-03-24
- 2025-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $22.00K.
- 2024-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $71.00K.
- 2024-09-30: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $84.00K.
- 2024-06-30: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $96.00K.
| Period end | Finance Lease, Right-of-Use Asset, before Accumulated Amortization |
|---|---|
| 2025-12-31 | $22.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $71.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $84.00K 10-Q · filed 2024-11-18 |
| 2024-06-30 | $96.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $87.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $98.00K 10-K · filed 2025-03-24 |
| 2022-12-31 | $87.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |